March 11th, 2024

To Whom it May Concern,

Pursuant to 18 V.S.A. § 4637(c), please find below the required information submitted by Tilde Sciences LLC within 30 days of the notification pursuant to 18 V.S.A. § 4637(b) for Daraprim (pyrimethamine) 25 mg tablets.

(1) a description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	Daraprim (pyrimethamine) is being distributed through an exclusive specialty pharmacy model in the US with no plans for traditional advertising or promotion. The company maintained the WAC price that was established by the prior manufacturer ($750/pill). This pricing will enable Tilde to fund manufacturing and maintenance fees; offer high touch patient services, copay support, and free goods for uninsured; and recoup the cost of acquisition.
(2) the estimated volume of patients who may be prescribed the drug	The company expects ~20 patients/month to be prescribed the drug.
(3) whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval	No
(4) the date and price of acquisition if the drug was not developed by the manufacturer	The company acquired the drug in September of 2023 through an asset purchase agreement totaling $650,000 for the rights to Daraprim and Vecamyl. Vecamyl is FDA approved, but is unavailable in the market due to supply issues.

Please let me know if you have any further questions.

Sincerely,

Robert Antoine
Chief Operations Officer